Adding a fixed-dose combination of isosorbide dinitrate and hydralazine (ISDN-H) to standard heart failure therapy dramatically improved survival, decreased hospitalizations, and improved quality of life for African Americans, according to the results of the African American Heart Failure Trial (A-HeFT).

The trial, cosponsored by NitroMed and the Association of Black Cardiologists, studied 1,050 self-identified African Americans with heart failure. This clinical trial was stopped early due to the significant survival benefit seen with the experimental combination drug.

About this site

This Web site explores this novel approach to heart failure treatment in a targeted population and gives the clinician information about the current theory on the mechanism of action of ISDN-H.

In addition, the lead investigators provide answers to common questions about A-HeFT's unique study design and its implications for future drug trials.